{"id":"W2599098340","doi":"10.1016/j.cllc.2017.03.010","title":"LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nintedanib; Pemetrexed; Medicine; Bevacizumab; Oncology; Internal medicine; Mesothelioma; Clinical endpoint; Maintenance therapy; Vascular endothelial growth factor; Carboplatin; Interim analysis; Cisplatin; Surgery; Chemotherapy; Clinical trial; Pathology; Idiopathic pulmonary fibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01275853,0.003446266,0.003745844,0.0009904036,0.001749199,0.001782352,0.002096422,0.002981975,0.007182762],"category_scores_gemma":[0.006010799,0.002156226,0.00238274,0.000837297,0.003997387,0.001387278,0.0008664606,0.005089488,0.002023829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001333545,"about_ca_system_score_gemma":0.005333354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007469207,"about_ca_topic_score_gemma":0.001929422,"domain_scores_codex":[0.9943573,0.00374848,0.0003552912,0.0005895319,0.0003982021,0.0005512877],"domain_scores_gemma":[0.9976428,0.0005371129,0.0003896809,0.0004184831,0.0002681635,0.0007436762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9369475,0.02145305,0.002311372,0.001318785,0.0008848647,0.0001128404,0.0002290038,0.001416559,0.01294752,0.001436192,0.0015727,0.01936964],"study_design_scores_gemma":[0.8639145,0.125188,0.002192999,0.00006826223,0.0006290847,0.00005431202,0.0000414988,0.0005598589,0.001569543,0.0005096059,0.005229968,0.00004242975],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.5155221,0.00641065,0.01239617,0.002883472,0.002287691,0.4475189,0.005181622,0.0004594528,0.007340068],"genre_scores_gemma":[0.5866185,0.002764907,0.02824993,0.003769053,0.001506435,0.3697905,0.002156728,0.000106828,0.005037124],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01275853,"threshold_uncertainty_score":0.06747431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02408420042486542,"score_gpt":0.3455455358566427,"score_spread":0.3214613354317772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}